Articles by Aparna R. Parikh, MD
Identifying Ideal Candidates for Triplet Therapy in mCRC Treatment
ByAparna R. Parikh, MD,Marwan G. Fakih, MD,Richard Kim, MD,Scott Paulson, MD,Mark A. Lewis, MD,Joleen M. Hubbard, MD Considerations for patients to receive aggressive mCRC therapy regimens are navigated by the panelists.
Fatigue Associated with Bevacizumab, Fruquintinib, TAS-102 Therapies
ByAparna R. Parikh, MD,Marwan G. Fakih, MD,Richard Kim, MD,Scott Paulson, MD,Mark A. Lewis, MD,Joleen M. Hubbard, MD Side effect profiles driven by fruquintinib use are discussed.
Consideration for Fruquintinib Dosing and Titration
ByAparna R. Parikh, MD,Marwan G. Fakih, MD,Richard Kim, MD,Scott Paulson, MD,Mark A. Lewis, MD,Joleen M. Hubbard, MD Mark A Lewis, MD, and Scott Paulson, MD, share their experiences utilizing fruquintinib.
Utilizing RWE to Derive Optimal Treatment Strategy for Refractory mCRC
ByAparna R. Parikh, MD,Marwan G. Fakih, MD,Richard Kim, MD,Scott Paulson, MD,Mark A. Lewis, MD,Joleen M. Hubbard, MD Richard Kim, MD, discusses the significance of real-world evidence when selecting treatment sequencing strategy.
Dose Modifications and Tolerability Associated with mCRC Treatment Regimens
ByAparna R. Parikh, MD,Marwan G. Fakih, MD,Richard Kim, MD,Scott Paulson, MD,Mark A. Lewis, MD,Joleen M. Hubbard, MD Managing dose adjustments and tolerability in metastatic colorectal cancer (mCRC) treatment regimens for optimal efficacy is underscored.
FRESCO-2 Study Highlights
ByAparna R. Parikh, MD,Marwan G. Fakih, MD,Richard Kim, MD,Scott Paulson, MD,Mark A. Lewis, MD,Joleen M. Hubbard, MD Medical experts provide key takeaways and impacts from the FRESCO-2 study.
Compounding Impact of TAS-102 and Bevacizumab in mCRC Treatment
ByAparna R. Parikh, MD,Marwan G. Fakih, MD,Richard Kim, MD,Scott Paulson, MD,Mark A. Lewis, MD,Joleen M. Hubbard, MD Marwan G Fakih, MD, drives a discussion highlighting a significant combination therapy in mCRC treatment.
Fruquintinib MoA and Toxicity Profile Overview
ByAparna R. Parikh, MD,Marwan G. Fakih, MD,Richard Kim, MD,Scott Paulson, MD,Mark A. Lewis, MD,Joleen M. Hubbard, MD Key safety considerations for the use of fruquintinib are explored.
Evaluating 3L Treatment Landscape Evolution
ByAparna R. Parikh, MD,Marwan G. Fakih, MD,Richard Kim, MD,Scott Paulson, MD,Mark A. Lewis, MD,Joleen M. Hubbard, MD Dr Parikh drives a conversation surrounding 3L treatment for patients diagnosed with metastatic colorectal cancer.
Overview of Current mCRC Treatment Landscape
ByAparna R. Parikh, MD,Marwan G. Fakih, MD,Richard Kim, MD,Scott Paulson, MD,Mark A. Lewis, MD,Joleen M. Hubbard, MD Medical experts open a discussion providing an update on the current impact of metastatic colorectal cancer and common treatment strategies.
Metastatic Colorectal Cancer: Ongoing Challenges and Future Directions in Care
ByJohn Marshall, MD, Georgetown University Lombardi Comprehensive Cancer Center,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic,Aparna R. Parikh, MD,Stacey A. Cohen, MD Closing out their panel on metastatic colorectal cancer, expert oncologists consider ongoing challenges and future evolutions within the treatment landscape.
HER2+ Metastatic Colorectal Cancer: Clinical Trial Data With T-DXd
ByJohn Marshall, MD, Georgetown University Lombardi Comprehensive Cancer Center,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic,Aparna R. Parikh, MD,Stacey A. Cohen, MD Focused discussion on clinical trial data with trastuzumab deruxtecan in the setting of HER2+ metastatic colorectal cancer.
HER2+ Metastatic Colorectal Cancer: Clinical Trial Data With Tucatinib
ByJohn Marshall, MD, Georgetown University Lombardi Comprehensive Cancer Center,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic,Aparna R. Parikh, MD,Stacey A. Cohen, MD A panel of oncologists shares comprehensive insight to clinical trial data with tucatinib in patients with HER2+ metastatic colorectal cancer.
Assessing HER2 Expression in Metastatic Colorectal Cancer
ByJohn Marshall, MD, Georgetown University Lombardi Comprehensive Cancer Center,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic,Aparna R. Parikh, MD,Stacey A. Cohen, MD Switching their focus to HER2+ metastatic colorectal cancer, panelists discuss best practices in testing HER2 to aid in the timely selection of best available therapies.
Novel Combination Strategies in BRAF-Mutant Metastatic Colorectal Cancer
ByJohn Marshall, MD, Georgetown University Lombardi Comprehensive Cancer Center,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic,Aparna R. Parikh, MD,Stacey A. Cohen, MD Expert perspectives on novel combination and immunotherapy strategies within BRAF-mutated metastatic colorectal cancer management.
Metastatic Colorectal Cancer: Tumor Sidedness and EGFR-Targeted Therapy
ByJohn Marshall, MD, Georgetown University Lombardi Comprehensive Cancer Center,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic,Aparna R. Parikh, MD,Stacey A. Cohen, MD Shared insight to the importance of tumor sidedness and its impact on the selection of EGFR-targeted therapy in metastatic colorectal cancer.
BRAF V600E–Mutant Metastatic Colorectal Cancer: BREAKWATER Study
ByJohn Marshall, MD, Georgetown University Lombardi Comprehensive Cancer Center,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic,Aparna R. Parikh, MD,Stacey A. Cohen, MD Key opinion leaders in metastatic colorectal cancer management review data from the BREAKWATER study in BRAF-V600E–mutated disease.
Treatment Options for BRAF V600E–Mutant Metastatic Colorectal Cancer
ByJohn Marshall, MD, Georgetown University Lombardi Comprehensive Cancer Center,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic,Aparna R. Parikh, MD,Stacey A. Cohen, MD Centering discussion on patients with BRAF-V600E mutations in metastatic colorectal cancer, panelists reflect on the treatment armamentarium in this setting.
Colorectal Cancer: Evolving Role of ctDNA Testing in Practice
ByJohn Marshall, MD, Georgetown University Lombardi Comprehensive Cancer Center,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic,Aparna R. Parikh, MD,Stacey A. Cohen, MD A brief review of how circulating tumor DNA testing has impacted the real-world management of patients with metastatic colorectal cancer.
ctDNA and MRD Testing in Nonmetastatic Colorectal Cancer
ByJohn Marshall, MD, Georgetown University Lombardi Comprehensive Cancer Center,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic,Aparna R. Parikh, MD,Stacey A. Cohen, MD A focused discussion on the respective roles of circulating tumor DNA and minimal residual disease testing in the management of patients with nonmetastatic colorectal cancer.
Biomarker Testing in Metastatic Colorectal Cancer
ByJohn Marshall, MD, Georgetown University Lombardi Comprehensive Cancer Center,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic,Aparna R. Parikh, MD,Stacey A. Cohen, MD Expert panelists provide their perspective on the current state of molecular testing in metastatic colorectal cancer and how it impacts treatment pathways.
Audience Q&A: Best Practices in Managing HER2-Amplified CRC
ByTanios Bekaii-Saab, MD, FACP, Mayo Clinic,Cathy Eng, MD, Vanderbilt University,Pashtoon M. Kasi, MD, MBBS, MS,Aparna R. Parikh, MD Fielding questions from the audience, expert oncologists discuss clinical trials, molecular testing, and early-stage disease in the context of HER2-amplified colorectal cancer.
Evolutions in the HER2-Amplified CRC Treatment Landscape
ByTanios S. Bekaii-Saab, MD, Mayo Clinic,Cathy Eng, MD, Vanderbilt University,Pashtoon M. Kasi, MD, MBBS, MS,Aparna R. Parikh, MD Looking toward the future management of HER2-amplified colorectal cancer, panelists reflect on ongoing clinical trials and evolving treatment strategies.
Real-World Use of HER2-Directed Therapies in Colorectal Cancers
ByTanios S. Bekaii-Saab, MD, Mayo Clinic,Cathy Eng, MD, Vanderbilt University,Pashtoon M. Kasi, MD, MBBS, MS,Aparna R. Parikh, MD Expert perspectives on the real-world use of HER2-directed therapies in patients with HER2-amplified colorectal cancer.
HER2-Amplified Colorectal Cancer: Clinical Trial Data
ByTanios S. Bekaii-Saab, MD, Mayo Clinic,Cathy Eng, MD, Vanderbilt University,Pashtoon M. Kasi, MD, MBBS, MS,Aparna R. Parikh, MD A focused discussion on HER2-amplified colorectal cancer and respective clinical trials that inform use of targeted agents in this setting.
Treatment Algorithm for Metastatic Colorectal Cancer
ByTanios S. Bekaii-Saab, MD, Mayo Clinic,Cathy Eng, MD, Vanderbilt University,Pashtoon M. Kasi, MD, MBBS, MS,Aparna R. Parikh, MD Broadening their conversation, expert oncologists define the treatment algorithm for patients diagnosed with colorectal cancer.
Role of Circulating Tumor DNA Testing in Colorectal Cancer
ByTanios S. Bekaii-Saab, MD, Mayo Clinic,Cathy Eng, MD, Vanderbilt University,Pashtoon M. Kasi, MD, MBBS, MS,Aparna R. Parikh, MD In the context of colorectal cancer clinical trials, panelists reflect on the role of liquid biopsies to help inform treatment decisionmaking.
Role of HER2 Expression in Colorectal Cancer
ByTanios S. Bekaii-Saab, MD, Mayo Clinic,Cathy Eng, MD, Vanderbilt University,Pashtoon M. Kasi, MD, MBBS, MS,Aparna R. Parikh, MD A brief review of HER2 amplification and how it may impact the treatment pathway for patients with a diagnosis of colorectal cancer.
Colorectal Cancer: An Overview on Molecular Profiling
ByTanios S. Bekaii-Saab, MD, Mayo Clinic,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Pashtoon M. Kasi, MD, MBBS, MS,Aparna R. Parikh, MD Shared insight on appropriate molecular lab testing options that should be explored following a diagnosis of colorectal cancer.
Colorectal Cancer: Prevalence, Workup, and Molecular Subtypes
ByTanios S. Bekaii-Saab, MD, Mayo Clinic,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Pashtoon M. Kasi, MD, MBBS, MS,Aparna R. Parikh, MD Opening their discussion on colorectal cancer, expert panelists consider its growing prevalence and highlight key molecular subtypes.
